Generation of SARS-CoV-2 escape mutations by monoclonal antibody therapy.
Journal article
Ragonnet-Cronin M. et al, (2023), Nat Commun, 14
COVID-19 vaccination, risk-compensatory behaviours, and contacts in the UK.
Journal article
Buckell J. et al, (2023), Scientific reports, 13
Evaluation of T cell responses to naturally processed variant SARS-CoV-2 spike antigens in individuals following infection or vaccination.
Journal article
Yin Z. et al, (2023), Cell Rep, 42
Persistence of immune response in heterologous COVID vaccination schedules in the Com-COV2 study - a single-blind, randomised trial incorporating mRNA, viral-vector and protein-adjuvant vaccines.
Journal article
Shaw RH. et al, (2023), J Infect
Rapid escape of new SARS-CoV-2 Omicron variants from BA.2-directed antibody responses
Journal article
Dijokaite-Guraliuc A. et al, (2023), Cell Reports, 42, 112271 - 112271
Evolution of long-term vaccine-induced and hybrid immunity in healthcare workers after different COVID-19 vaccine regimens.
Journal article
Moore SC. et al, (2023), Med (New York, N.Y.), 4, 191 - 215.e9
Continuous population-level monitoring of SARS-CoV-2 seroprevalence in a large European metropolitan region
Journal article
Emmenegger M. et al, (2023), iScience, 26, 105928 - 105928
A delicate balance between antibody evasion and ACE2 affinity for Omicron BA.2.75
Journal article
Huo J. et al, (2023), Cell Reports, 42, 111903 - 111903
Guillain-Barré Syndrome Following Zika Virus Infection Is Associated With a Diverse Spectrum of Peripheral Nerve Reactive Antibodies.
Journal article
Davies AJ. et al, (2023), Neurology(R) neuroimmunology & neuroinflammation, 10
Antigenic characterization of SARS-CoV-2 Omicron subvariant BA.4.6.
Journal article
Dijokaite-Guraliuc A. et al, (2022), Cell discovery, 8
CryoEM structures of the multimeric secreted NS1, a major factor for dengue hemorrhagic fever.
Journal article
Shu B. et al, (2022), Nature communications, 13
Humoral responses against SARS-CoV-2 Omicron BA.2.11, BA.2.12.1 and BA.2.13 from vaccine and BA.1 serum.
Journal article
Huo J. et al, (2022), Cell discovery, 8
Omicron-associated changes in SARS-CoV-2 symptoms in the United Kingdom
Journal article
Vihta1 KD. et al, (2022), Clinical Infectious Diseases
Fatal COVID-19 outcomes are associated with an antibody response targeting epitopes shared with endemic coronaviruses
Journal article
McNaughton AL. et al, (2022), JCI Insight, 7
Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum
Journal article
Tuekprakhon A. et al, (2022), Cell, 185, 2422 - 2433.e13
Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trial.
Journal article
Shaw RH. et al, (2022), The Lancet. Respiratory medicine
Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial.
Journal article
Liu X. et al, (2022), The Journal of infection, 84, 795 - 813
Potent cross-reactive antibodies following Omicron breakthrough in vaccinees
Journal article
Nutalai R. et al, (2022), Cell, 185, 2116 - 2131.e18